Table 5 Unadjusted and adjusted hazard ratios for the factors associated with OS to cisplatin/gemcitabine treatment among patients with MPM
HR (95% CI) | p-Value | HR (95% CI) | p-value | |
|---|---|---|---|---|
Sex | 1.21 (0.66–2.23) | 0.537 | ||
Age, years | 1.62 (0.90–2.95) | 0.108 | 2.77 (0.75–10.3) | 0.125 |
Tobacco exposure | 0.64 (0.35–1.16) | 0.141 | 0.82 (0.25–2.75) | 0.821 |
Exposure to asbestos | 0.72 (0.40–1.31) | 0.283 | ||
ECOG PS | 1.64 (0.79–3.43) | 0.186 | ||
Histology | 1.60 (0.66–3.84) | 0.297 | ||
Karnofsky | 0.59 (0.32–1.11) | 0.102 | 0.16 (0.04–0.75) | 0.019 |
Disease stage | 0.99 (0.53–1.87) | 0.979 | ||
ORR | 2.17 (1.25–3.78) | 0.006 | 1.55 (0.71–3.36) | 0.269 |
ERCC1 | 0.28 (0.12–0.63) | 0.002 | 0.24 (0.07–0.79) | 0.020 |
RRM1 | 0.32 (0.12–0.86) | 0.023 | ||
RRM2 | 0.60 (0.23–1.41) | 0.246 | ||
hENT-1 | 0.68 (0.34–1.39) | 0.290 |